摘要
目的：研究α１Ａ受体阻断剂——盐酸坦索罗辛对不同体积良性前列腺增生症（ＢＰＨ）的疗效。方法：对６０例症状性ＢＰＨ按前列腺体积大小分成三组：体积＜３０ｍｌ１３例，体积３０～４０ｍｌ２５例，体积＞４０ｍｌ２２例。分别给予盐酸坦索罗辛０．２ｍｇ口服，１次／ｄ，治疗观察６周。结果：三组患者主观症状明显改善；国际前列腺症状评分（ＩＰＳＳ）分别降低４１．１％、３９．８％、３９．２％；最大尿流率（ＭＦＲ）和平均尿流率（ＡＦＲ）分别提高２５．０％、２３．４％、２７．９％和２５．５％、２０．３％、２５．５％。其中４７例残余尿（ＰＶＲ）下降５１．６％（Ｐ＜０．０１）。三组之间ＩＰＳＳ评分，ＭＦＲ和ＡＦＲ变化率统计学上无显著性差异。盐酸坦索罗辛对所有患者前列腺体积、血压、脉搏无明显影响（Ｐ值均＞０．０５）。结论：盐酸坦索罗辛对不同体积ＢＰＨ患者的自觉症状、客观体征和生活质量有明显的改善作用。
Purpose: To
investigate the efficacy of tamsulosin for benign prostatic hyperplasia (BPH) with different
volume. Methods: From July 1997 to Oct. 1997,60 patients with symptomatic BPH were divided
by baseline prostate volume into 3 groups:volume <30 ml 13 cases;30￣40 ml 22
cases;volume >40 ml 25 cases and were received tamsulosin 0.2mg daily for 6 weeks. Results:
3 groups of patients had a clinically significant response to the treatment of tamsulosin,and
defined as those with 41.1%,39.8%,39.2% decrease in IPSS scores;25.0%,23.4%,27.9% and
25.5%,20.3%,25.5% improvement in maximal urinary flow rate (MFR) and average urinary flow
rate (AFR),respectively.There were no significant differences in IPSS scores,MFR and AFR
among 3 groups.Postvoid residual urine (PVR) decreased by 51.6% (P<0.01) in 47
patients.tamsulosin had no significant effect on prostatic volume,blood pressure and pulse rate
for all of the patients (P>0.05 respectively).Mild adverse effects were noticed. Conclusions:
tamsulosin can significantly improve symptoms,signs and life qualities which has no serious
adverse effects.
出处
《临床泌尿外科杂志》
1999年第7期287-290,共4页
Journal of Clinical Urology
关键词
前列腺增生
药物疗法
盐酸坦索罗辛
Prostatic hypertrophyAdrenergic alpha receptor blockadersUrination
disorders
